Mylan to buy Abbott’s non-US specialty, branded generics assets
The all-stock transaction is valued at about $5.3 billion
Generic drug maker Mylan Inc. said it would buy Abbott Laboratories’ specialty and branded generics business outside the US in an all-stock transaction valued at about $5.3 billion.
Abbott will receive 105 million shares of the combined company worth.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!